CN114980974A - 含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽 - Google Patents

含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽 Download PDF

Info

Publication number
CN114980974A
CN114980974A CN202080085549.9A CN202080085549A CN114980974A CN 114980974 A CN114980974 A CN 114980974A CN 202080085549 A CN202080085549 A CN 202080085549A CN 114980974 A CN114980974 A CN 114980974A
Authority
CN
China
Prior art keywords
amino acid
seq
acid sequence
isvd
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080085549.9A
Other languages
English (en)
Chinese (zh)
Inventor
H·罗美莱尔
A·布里格
S·科内利斯
B·东布雷希特
E·洛朗
M·丽格
T·索斯
J·帕克
B·威格勒
K·厄伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abelynx
Sanofi Aventis France
Original Assignee
Abelynx
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abelynx, Sanofi Aventis France filed Critical Abelynx
Publication of CN114980974A publication Critical patent/CN114980974A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN202080085549.9A 2019-12-09 2020-12-09 含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽 Pending CN114980974A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962945391P 2019-12-09 2019-12-09
US62/945,391 2019-12-09
EP20305064 2020-01-27
EP20305064.6 2020-01-27
PCT/EP2020/085304 WO2021116182A1 (en) 2019-12-09 2020-12-09 Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp

Publications (1)

Publication Number Publication Date
CN114980974A true CN114980974A (zh) 2022-08-30

Family

ID=73793214

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080085549.9A Pending CN114980974A (zh) 2019-12-09 2020-12-09 含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽

Country Status (14)

Country Link
US (4) US20210188965A1 (https=)
EP (1) EP4072674A1 (https=)
JP (2) JP7641968B2 (https=)
KR (1) KR20220123237A (https=)
CN (1) CN114980974A (https=)
AU (1) AU2020400938A1 (https=)
BR (1) BR112022010223A2 (https=)
CA (1) CA3163910A1 (https=)
CO (1) CO2022008813A2 (https=)
IL (1) IL293548A (https=)
MX (1) MX2022007035A (https=)
MY (1) MY208649A (https=)
TW (2) TW202530257A (https=)
WO (1) WO2021116182A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6871948B2 (ja) 2016-04-27 2021-05-19 アッヴィ・インコーポレイテッド 抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法
MX2022007035A (es) 2019-12-09 2022-06-23 Ablynx Nv Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp.
AU2021350156A1 (en) 2020-09-25 2023-06-08 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
IL308360A (en) * 2021-05-30 2024-01-01 Biolojic Design Ltd Engineered dual binding antibodies and uses thereof
EP4540284A2 (en) 2022-06-17 2025-04-23 Apogee Therapeutics, Inc. Antibodies that bind interleukin 13 and methods of use
US20240117038A1 (en) * 2022-07-18 2024-04-11 Ablynx N.V. Cx3cr1-binding compounds, methods and uses thereof
CN118005784A (zh) * 2022-11-08 2024-05-10 上海洛启生物医药技术有限公司 抗il-13长效纳米抗体序列及其应用
AR131494A1 (es) 2022-12-23 2025-03-26 Ablynx Nv Vehículos de conjugación a base de proteína
TW202448926A (zh) 2023-02-17 2024-12-16 比利時商艾伯霖克斯公司 結合新生兒fc受體之多肽
EP4435005A1 (en) 2023-03-24 2024-09-25 Sanofi Asthma treatment by blocking il-13 and tslp
AU2024247861A1 (en) 2023-03-24 2025-11-06 Sanofi Asthma treatment by blocking il-13 and tslp
CN121816362A (zh) * 2023-06-22 2026-04-07 派拉冈医疗公司 结合白细胞介素13和tslp或tslpr的抗体及其使用方法
AU2024334289A1 (en) 2023-08-25 2026-04-09 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
AR134102A1 (es) * 2023-10-12 2025-12-03 Innovent Biologics Suzhou Co Ltd ANTICUERPOS ANTI-IL-4Ra Y USOS DE LOS MISMOS
WO2025209486A1 (en) * 2024-04-02 2025-10-09 Keymed Biosciences (Chengdu) Co., Ltd. Antibodies targeting il-13 and tslp and uses thereof
WO2026041740A1 (en) 2024-08-21 2026-02-26 Sanofi Treatment of high-risk asthma by blocking il-13 and tslp
WO2026055143A2 (en) * 2024-09-03 2026-03-12 Attovia Therapeutics, Inc. Il13-binding polypeptides and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160264658A1 (en) * 2015-03-11 2016-09-15 Glaxosmithkline Intellectual Property Development Limited TSLP Binding Proteins
CN108473561A (zh) * 2015-11-27 2018-08-31 埃博灵克斯股份有限公司 抑制cd40l的多肽
CN109887553A (zh) * 2019-01-29 2019-06-14 杭州纽安津生物科技有限公司 针对肿瘤靶向药物耐药位点的多肽疫苗及其设计方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DK1027439T3 (da) 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
WO2004041863A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
AU2007237501A1 (en) 2006-04-14 2007-10-25 Ablynx N.V. DP-78-like nanobodies
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
AU2007293614A1 (en) * 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
JP5059119B2 (ja) * 2006-12-14 2012-10-24 シェーリング コーポレイション 操作された抗ｔｓｌｐ抗体
KR20110092328A (ko) * 2008-11-26 2011-08-17 글락소 그룹 리미티드 Ｉｌ-13에 결합하는 리간드
SG10201805064SA (en) 2011-06-23 2018-07-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2723771B1 (en) 2011-06-23 2019-09-11 Ablynx NV Serum albumin binding proteins
EP4707303A2 (en) 2014-05-16 2026-03-11 Ablynx NV Improved immunoglobulin variable domains
LT3374392T (lt) 2015-11-13 2022-01-25 Ablynx Nv Patobulinti serumo albuminą surišantys imunoglobulino kintami domenai
CA3003777A1 (en) * 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Pd1/ctla4 binders
AU2016357460B2 (en) 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
EP3426278B1 (en) * 2016-03-07 2024-01-03 Vib Vzw Cd20 binding single domain antibodies
BR112019010061A2 (pt) * 2016-11-16 2019-08-13 Ablynx Nv polipeptídeos de recrutamento de células t capazes de se ligarem ao cd123 e tcr alfa/beta
RU2022101604A (ru) 2016-12-07 2022-03-29 Аблинкс Нв Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
IL267897B2 (en) 2017-01-17 2025-02-01 Ablynx Nv Improved serum albumin binders
JP7219220B2 (ja) 2017-01-17 2023-02-07 アブリンクス エン．ヴェー． 改善された血清アルブミン結合剤
KR20210005872A (ko) * 2018-03-28 2021-01-15 오리오니스 바이오사이언시즈 인코포레이티드 이작용성 단백질 및 이의 작제물
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
MX2022007035A (es) * 2019-12-09 2022-06-23 Ablynx Nv Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160264658A1 (en) * 2015-03-11 2016-09-15 Glaxosmithkline Intellectual Property Development Limited TSLP Binding Proteins
CN108473561A (zh) * 2015-11-27 2018-08-31 埃博灵克斯股份有限公司 抑制cd40l的多肽
CN109887553A (zh) * 2019-01-29 2019-06-14 杭州纽安津生物科技有限公司 针对肿瘤靶向药物耐药位点的多肽疫苗及其设计方法

Also Published As

Publication number Publication date
WO2021116182A1 (en) 2021-06-17
US12492248B2 (en) 2025-12-09
US20220177565A1 (en) 2022-06-09
JP2025081540A (ja) 2025-05-27
JP2023504914A (ja) 2023-02-07
EP4072674A1 (en) 2022-10-19
IL293548A (en) 2022-08-01
TW202136302A (zh) 2021-10-01
MY208649A (en) 2025-05-22
US20210188965A1 (en) 2021-06-24
BR112022010223A2 (pt) 2022-09-06
CA3163910A1 (en) 2021-06-17
CO2022008813A2 (es) 2022-07-19
KR20220123237A (ko) 2022-09-06
JP7641968B2 (ja) 2025-03-07
MX2022007035A (es) 2022-06-23
US11840566B2 (en) 2023-12-12
US20220177566A1 (en) 2022-06-09
TW202530257A (zh) 2025-08-01
AU2020400938A1 (en) 2022-07-28
TWI861302B (zh) 2024-11-11
US12384840B2 (en) 2025-08-12
US20220177564A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
JP7641968B2 (ja) Ｉｌ－１３およびｔｓｌｐを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
US11208476B2 (en) Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP
JP7817994B2 (ja) Ｉｌ－１３およびｏｘ４０ｌを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
CN114981300B (zh) 包含靶向TNFα和IL-23的免疫球蛋白单个可变结构域的多肽
JP7719775B2 (ja) ＴＮＦαおよびＯＸ４０Ｌを標的とする免疫グロブリン単一可変ドメインを含むポリペプチド
JP7842101B2 (ja) ＩＬ－６およびＴＮＦ－αを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
US12258394B2 (en) IL-5 antibody, antigen binding fragment thereof, and medical application therefor
CN116783214A (zh) 包含靶向il-13和ox40l的免疫球蛋白单可变结构域的多肽
RU2836310C1 (ru) Полипептиды, содержащие одиночные вариабельные домены иммуноглобулинов, нацеливающиеся на il-13 и tslp
BR122024023752A2 (pt) Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina que se ligam a il-13 e/ou tslp, método de produção e usos dos mesmos, ácido nucleico, composição e uso da mesma, e hospedeiro ou célula hospedeira
CN116615453A (zh) 包含靶向IL-6和TNF-α的免疫球蛋白单可变结构域的多肽

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination